



SUPPLEMENTARY FIGURES AND TABLE



Supplementary Figure S1: miR-27b suppresses CCNG1 *in vivo*. **A.** qRT-PCR analysis of CCNG1 in tumors treated with miR-27b agomir or control. ****** $P < 0.01$. **B.** Western blotting analysis of CCNG1 in tumors treated with miR-27b agomir or control.



Supplementary Figure S2: The effects of miR-27b and CCNG1 on cell proliferation. **A.** Inhibitors for miR-27b was transfected into SGC7901 cells and cell proliferation was measured by MTT assays. **B.** SGC7901/VCR cells were transfected with mimics for miR-27b and MTT assays were performed to examine cell proliferation. **C.** Knockdown of CCNG1 by siRNAs in SGC7901/VCR cells suppressed cell proliferation. * $P < 0.05$.

Supplementary Table S1: The association of miR-27b and miR-508-5p with the clinicopathologic features in GC tissues from tissue microarrays

Variables	N	miR-27b				P	miR-508-5p				P
		-	+	++	+++		-	+	++	+++	
<i>Age</i>						0.99					0.89
≥ 60	101	13	25	29	34		14	31	30	26	
< 60	13	2	3	4	4		1	5	4	3	
<i>Gender</i>						0.35					0.17
Male	53	6	17	15	15		10	19	12	12	
Female	61	9	11	18	23		5	17	22	17	
<i>Differentiation</i>						0.61					0.32
Well - Moderate	40	3	10	13	14		7	11	9	13	
Poor	74	12	18	20	24		8	25	25	16	
<i>T</i>						0.69					0.23
T ₁ -T ₂	15	1	5	5	4		2	8	2	3	
T ₃ -T ₄	99	14	23	28	34		13	28	32	26	
<i>N</i>						0.11					0.54
N ₀ -N ₁	49	10	14	13	12		6	13	18	12	
N ₂ -N ₃	65	5	14	20	26		9	23	16	17	
<i>Metastasis</i>						0.88					0.38
M ₁	10	1	3	2	4		0	3	5	2	
M ₀	104	14	25	31	34		15	33	29	27	
<i>AJCC Staging</i>						0.23					0.22
I-II	48	9	11	16	12		3	17	17	11	
III-IV	66	6	17	17	26		12	19	17	18	